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Abstract
OBJECTIVE: The objective of this selective EBM review is to determine whether or not
HMG-CoA Inhibitors (Statins) are an effective treatment for erectile dysfunction (ED).
STUDY DESIGN: Systematic review of three English language randomized controlled
trials published between 2011-2013.
DATA SOURCES: Three randomized controlled trials published in peer-reviewed
journals comparing the effects of statins on erectile function found using the PubMed
database.
OUTCOMES MEASURED: The outcomes measured included erectile function,
assessed using the International Index of Erectile Dysfunction Questionnaire (IIEF) in all
three studies and Nocturnal Penile Tumescence (NPT) in one study, and male ED-quality
of life using the MED-QoL Questionnaire.
RESULTS: Two studies in the review show an insignificant improvement in erectile
function of participants taking a statin vs. a placebo. However, one study showed a
statistically significant difference in erectile function in participants taking a statin vs. no
medication at all. Additionally, one of the studies showed a significant improvement in
MED-quality of life in men taking a statin vs. a placebo. Although two of these studies
showed no statistically significant improvement in erectile function with use of a statin,
they both showed potential in statin use with a larger improvement for men with more
severe ED compared to men with a lesser degree of ED.
CONCLUSIONS: Based on these studies, the use of statins for treatment for ED cannot
be justified. Trivedi and colleagues, as well as Masttalir and colleagues, both showed no
significant difference in erectile function in participants with use of statins. However,
Gokce et al showed statin use in men with ED does in fact improve their erectile function
compared to men taking no medication at all. Although two studies showed no
significant improvement in erectile function they both showed a larger improvement in
men with more severe ED and one study showed a significant improvement in male EDquality of life. Further investigation should continue as this proves there is lead way for
the use of statins for their effect in erectile function.
Key Words: Erectile dysfunction, statins

INTRODUCTION
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Erectile dysfunction (ED) is defined as the inability for a man to achieve and
maintain an erection firm enough for sexual performance1 . In men without ED, physical
and psychological stimulation causes an increase in blood flow to the penis resulting in
erection1. There are many causes of ED ranging from physical issues to emotional or
psychological1. One common physical cause of ED is damage to penile arteries resulting
in reduced blood flow, often a consequence of other disease processes such as HTN, DM,
and atherosclerosis1. This paper evaluates three randomized controlled trials comparing
the efficacy of a statin as an oral medication for improving erectile function in patients
with ED.
This topic is relevant to both patients and the PA practice due to its commonality
and because it impacts patients of all races both physically and psychologically2. It is
believed that ED may be a predictor of future arterial disease of larger vessels such as the
coronary arteries, which in turn may lead to fatal consequences2. ED is a major cause of
male sexual dysfunction and affects many men in the US1. It is estimated that 30 million
men in the United States have ED1. 4% of men in their 50’s, 17% of men in their 60’s,
and 47% of men older than 75 are unable to achieve an erection1. Each year, ED results
in more than 500,000 visits to physician offices3. Incidence in ED increases with age,
therefore as life expectancy increases, prevalence of ED will also increase4.
Treatment for ED is very costly for individuals in the United States. Although the
exact number for total healthcare cost of ED has not been identified, according to data
from the Defense Health Agency, the Department of Defense spent 41.6 million dollars
on Viagra and 84.24 million total drugs on ED in 20145. Viagra is one of the most
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common medications used to treat ED and within the first 8 months that it became

available on the market 2.9 million prescriptions were written3. In addition, in 2011 an
article published by Clinical Pharmacology and Therapeutics stated that over 1 billion
dollars is spent annually worldwide on the three most popular PDE inhibitor drugs for the
treatment of ED6.
Contrary to popular belief, erectile dysfunction is not a normal part of aging7.
Penile erection occurs as an outcome of an increase in NO that leads to vasodilation7. ED
is an end result of endothelial dysfunction due to a change in NO, which in turn causes
vasoconstriction of blood vessels and decreased blood flow to the penis7. It has been
found that there is an association with vascular disease in about 50% of men older than
50 y/o with ED7.
Treatment for ED involves decreasing risk factors that may lead to chronic health
issues and consequently ED. This usually begins with lifestyle changes including
smoking cessation, reducing alcohol consumption, losing weight and exercising. If ED is
due to psychological issues, psychotherapy is recommended. Drug therapy such as oral
medications like phosphodiesterase (PDE-5) inhibitors and testosterone or injectable
medications like papaverine hydrocholoride, phentolamine, or alprostadil are often used.
Additional treatment modalities include vacuum devices and surgery such as penile
prosthesis or vascular reconstruction1.
As stated previously, ED is highly correlated to vascular dysfunction1. Some risk
factors for endothelial dysfunction include atherosclerotic disease, obesity, dyslipidemia,
systemic arterial hypertension and diabetes mellitus, which are often found in men with
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ED7. It is proposed that lowering lipid levels via statins may show improvement in
erectile function in men with ED.
OBJECTIVE

The objective of this selective EBM review is to determine weather or not statins
are an effective treatment for erectile dysfunction.
SEARCH STRATEGY METHODS
The studies used in this systematic review included two randomized, double
blind, placebo controlled clinical trials and one randomized, single blind, controlled trial.
The population studied included males diagnosed with erectile dysfunction. The
intervention used in each of the studies was an oral statin medication. The population
was compared to an experimental group who received either a visually matched placebo
or no treatment. The outcomes measured in the studies included erectile function and
male ED-specific quality of life.
All articles were published in English language in peer-reviewed journals and
searched usimg the PubMed database. All studies were discovered using the keywords
“erectile dysfunction” and “statins” and were chosen by relevance to the clinical question
and the required standards set forth by the syllabus (POEMS). Inclusion criteria for the
sources were randomized, controlled, and double or single blind studies, which used
statins as an intervention for ED. Exclusion criteria varied between studies but consisted
of history of acute MI or stroke, DM, Peyronie’s disease, hypogonadism,
hyperprolactinemia, any active inflammatory or infectious disease, previously underwent
radical prostatectomy, pelvic surgery or radiation therapy, PDE-5 inhibitor usage 6
months prior to enrollment, neurologic or mental problems, liver or hepatic insufficiency,
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use of nitrates, taking antihypertensive or lipid lowering medications, and not a high

cardiovascular risk. Statistics used in this review included p-values, mean change from
baseline, standard deviation, numbers needed to treat (NNT), relative benefit increase
(RBI), and absolute benefit increase (ABI). The specific studies demographics and
characteristics can be found in Table 1.

Table 1: Demographics and Characteristics of included studies
Study

Type

Gokce 5 (2012)

Single
blind
RCT

#Pts Age
(yrs)
134 3170

Mastalir6 (2011) Double 43
blind
RCT

3575

Trivedi7 (2013)

≥40

Double 173
blind
RCT

Inclusion
criteria
30-70 y/o male
pts, normal
libido, IEF <
17, No previous
use of PDE5
inhibitors,
normal serum
testosterone
levels
(>300ng/ml)

Exclusion criteria

W/D Interventions

History of any
14
pelvic surgery,
having any kind of
medication for ED,
having any
neurologic or
mental problems,
liver or hepatic
insufficiency, use
of nitrates, use of
antiandrogens
Men aged 35History of acute MI 2
75 years with
or stroke, DM,
ED (IIEF < 22), Peyronie’s disease,
levels of usCRP hypogonadism,
≥ 1.1mgl-1 and
hyperprolactinemia,
or any active
no other
inflammatory or
medical
indication or
infectious disease,
contraindication alcohol abusers,
previously
underwent radical
prostatectomy,
pelvic surgery, or
radiation therapy,
PDE5 inhibitor
usage 6 months
prior to enrollement
Men aged ≥ 40 IIEF >21, Diastolic 40
with untreated
BP > 100, Systolic
ED (score <22
BP > 170, HDL >

Atorvastatin
10 mg/day
for 3 months

Simvastatin
20mg/day
for 6 months

Simvastatin
40mg/day
for 6 months

on the IIEF),
were not
receiving lipid
lowering or
antihypertensive
medication, and
not at high
cardiovascular
risk
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7.5, Triglycerides >
5, testosterone < 8,
ALT > 66, Creatine
Kinase > 750,
Angina, on BP
treatment, Other
ED therapy, Other
statin therapy, GP
exclude, Lactose
intolerance

OUTCOME MEASURES
An outcome measured in all three studies was erectile function. Erectile function
was measured via the IIEF questionnaire in all three studies and also using the Nocturnal
Penile Tumescence test in Gokce et al. Scores for the IIEF were classified as severe = 511 and mild-moderate = 12-21 in Tivedi et al, and normal ≥ 26, mild = 22-25, mildmoderate = 17-21, moderate = 11-16, and severe ≤ 10 in Mastalir et al. Normal NPT was
defined as an erectile event of at least 60% rigidity on the tip of the penis with the
duration of at least 10 minutes7. Male ED – specific quality of life was a secondary
outcome measured in Trivedi et al by using the MED-QoL questionnaire.
RESULTS
All three studies that are included in this review are randomized controlled trials
that assessed the effectiveness of statin medications for treatment of erectile dysfunction.
The population included in all three studies was men over the age of 30. For the
comparison group two studies used a visually matched placebo and one study used no
treatment at all. All three studies contained dichotomous data that could be used to
calculate RBI, ABI, and NNT.
In the study by Mastalir et al, 43 patients with erectile dysfunction and endothelial
dysfunction were randomly assigned to either the Simvastatin group (n=21) or the
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placebo group (n=20) to determine the effectiveness of statin medication on erectile
function. Those with a history of acute MI or stroke, DM, Peyronie’s disease,
hypogonadism, hyperprolactinemia, any active inflammatory or infectious disease,

alcohol abusers, previously underwent radical prostatectomy, pelvic surgery, radiation
therapy, or PDE5 inhibitor usage 6 months prior to enrollment were excluded from the
study. Patients received a single nightly capsule of either 20 mg of Simvastatin or
placebo, which was distributed in a double-blinded manner for 6 months. Erectile
function was then assessed using the IIEF questionnaire, which was dispersed at
enrollment and repeated every 2 months for 6 months. The severity of erectile function
was evaluated by IIEF erection function domain (normal ≥ 26, mild ED = 22-25, mildto-moderate ED = 17-21, moderate ED = 11-16, and severe ED ≤ 10). Analysis was
performed by intention-to-treat.

Of the 43 patients enrolled in the study, 2 patients were lost during follow up for
unknown reasons, leaving a total of 41 patients at the end of the trial. No deaths were
reported and the only adverse events experienced were insomnia by one patient in each
group and dyspepsia by one patient in the placebo group. The results of this study show
no statistically significant difference in erectile function after 6 months of treatment with
simvastatin compared to placebo (p=.733). However, this study did show improvement in
severity of ED by a change in mean baseline although it was not statistically significant
(p=.330). At the start of the study 74% of patients of both groups had moderate-to-severe
dysfunction. After 6 months, 83% of the placebo group advanced to mild ED compared
to 100% of the simvastatin group. The data demonstrated a relative benefit increase
(RBI) of 20.5% and an absolute benefit increase (ABI) of 17%. The number needed to
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treat (NNT) was 6, therefore 6 patients needed to be treated with simvastatin in order for
1 more patient to experience evolution from severe ED to a more mild form.
In the study by Trivedi et all, 173 patients with ED and no other significant CV

risk factors were randomly assigned to two groups in which they received either 40 mg of
simvastatin or placebo in a double-blind manner daily for 6 months. Subjects were
excluded if they had an IIEF >21, diastolic BP > 100, systolic BP > 170, HDL > 7.5,
Triglycerides > 5, testosterone < 8, ALT > 66, Creatine Kinase > 750, angina, were on
BP treatment, other ED or statin therapy, GP exclude, or were lactose intolerant. Erectile
function was assessed by the IIEF questionnaire that was distributed at baseline and
repeated at 3 months and 6 months. The score was then categorized as severe (score 511) or mild/moderate (score 12-21). Sexual health-related quality of life was a secondary
outcome assessed and was measured at baseline, 3 months, and 6 months using the male
ED-specific quality of life questionnaire. Analysis was performed by intention-to-treat.
Of the 173 patients enrolled, 40 patients withdrew, leaving a total of 133 at the
end of the study and a total of 128 that completed the IIEF questionnaire. There were a
total of 126 adverse events reported and 5 were considered to be serious but not related to
the study medication. No deaths were recorded. The results of this study show no
statistically significant difference in erectile function with use of Simvastatin compared
to placebo by a change in mean from baseline (1.28 vs 0.07, p = 0.27) with 95% CI.
However, the study did reveal a statistically significant change in individuals that started
with severe ED on statins compared to placebo (p < 0.001). This data demonstrated an
RBI of 39.1%, ABI of 11%, and the NNT was 9. The men in the statin group showed a
statistically larger improvement in MED-QoL compared to the placebo group (5% vs 2%,
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p = 0.03), which was largest in men with severe ED. The data from the men using a

statin with severe ED demonstrated an RBI of 140%, ABI of .07, and the NNT was 15.
Table 2: Analysis of outcomes in men that progressed from a more severe ED to a
lesser degree of ED by Mastalir et al and Trivedi et al
Study

Number of

Relative benefit

Absolute

Number needed

patients

increase (RBI)

benefit increase

to treat (NNT)

(ABI)
Mastalir et al

41

20.5%

17%

6

Trivedi et al

128

39.1%

11%

9

Table 3: Results of MED-QOL in men with severe erectile function by Trivedi et al
RBI

ABI

NNT

140%

7%

15

The study done by Gockse et al included 120 participants with moderate to severe
ED that were randomly assigned to either a group receiving 10 mg Atorvastatin or
placebo daily, or 20 mg tadalafil three time per week for 3 months with treatment being
distributed in a single-blind manner. For the purpose of this review the tadalafil group
was excluded. Individuals were excluded if they had a history of any pelvic surgery,
having any kind of medication for ED, having any neurologic or mental problems, liver
or hepatic insufficiency, use of nitrates, or use of antiandrogens. Erectile function was
evaluated by the IIEF questionnaire and NPT test at baseline and again at the end of the
study. Analysis was performed by intention-to-treat.
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Of the 134 patients in the study, 45 were assigned to both the atorvastatin group

and to the no treatment group. 1 patient in the atorvastatin group and 2 patients in the no
treatment group were lost to follow up. 3 individuals discontinued in the atorvastin group
and 4 discontinued in the no treatment group. The total number of patients included at
that end of the study from the atorvastatin group (n=41) and no treatment group (n=39)
was 80. The results of this study show a statistically significant improvement in erectile
function by IIEF scores in the artovastatin group compared to the no treatment group by
means +/- SD (7 +/- 2.2 vs 2 +/- 0.6, p = 0.001). It also shows a statistically significant
improvement in erectile function by positive NPT test results in the atorvastatin group
compared to the no treatment group (39% vs 7.6%, p=0.001). The data for the NPT test
demonstrates an RBI of 413%, ABI of 31.4% and the NNT was 3.
Table 4: Results of NPT test for improvement in erectile function by Gockse et al
Number of patients

RBI

ABI

NNT

80

413%

31.4%

3

DISCUSSION
The studies in this review analyze statin medications as a form of treating ED. It
is estimated that 40% of presentations of ED are due to vascular damage through
hyperlipidemia with the exclusion of effects from DM 4.These studies were performed to
evaluate the pleiotropic effects of statin medications on vascular impairment to promote
better erectile function. The results of all three studies showed conflicting evidence as
two studies found no statistically significant change in erectile function with statin use
compared to placebo and the third study found a statistically significant improvement in
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erectile function with use of a statin compared to no medication at all. Although the first
two studies did not find a significant difference they did find a larger improvement in
erectile function in men that had a more severe form of ED compared to a lesser degree

of ED, yet only one of the two studies found it to be statistically significant. The Trivedi
et al study also found a statistically significant improvement in sexual health related
quality of life in the simvastatin group compared to placebo.
The primary use of statin medications is for hyperlipidemia. Statins are the most
common drug class used to lower cholesterol levels with 93% of adults on lipid-lowering
agents using them8. Although used by many, statin medications are known for their side
effects of myopathy and, worst-case scenario, rhabdomyolisis9. Rhabdomyolisis is a lifethreatening condition caused by muscle break down but is rare due to the ability to
monitor CK levels if a patient presents with complaints indicating of this condition9.
Statin medications have also shown to increase LFT’s9. FDA has recently denied black
box warnings for both rhabdomyolisis and serious increase in LFTs because of the rare
chance that they will occur10, 11. Other possible side effects from statins include GI upset,
rash, memory loss, or hyperglycemia. Statins should be avoided in pregnancy and
acute/chronic liver disease9.
Several limitations are found within this review. The population size
within two of the studies were fairly small, with a total of 41 patients in Mastalir et al and
80 patients in Gokce. Other limitations found with the Mastalir et al study was the low
dose of Simvastatin used and the lack of physiological study of penile vascular function.
This limitation was also seen in Trivedi et al, therefore these studies results are based off
of subjective matters. All articles are limited in the fact that they do not take into account
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the personal relationships of the participants, which could be a major influence in ED.

Two other limitations that were found in the Gokce et al study were a lack of placebo and
the fact that it was single blind. Gocke et al states within the study that they feel these
limitations are made up for by their ability to use the NPT test, which were objective
findings.
CONCLUSION
This review shows inconclusive evidence for the use of statin medication as a
treatment for ED. Two studies showed no benefit in erectile function and one study
showed advantage in statin use for ED. Although no benefit was found in two studies,
the authors of these articles did find minor improvement in erectile function when
looking at men with more severe ED. In the study by Trivedi et al, the results suggest
that simvastatin would also be a cost-effective strategy. According to these results, there
may still be potential for statins to be used to treat ED or at least augment therapy. Only
one randomized controlled trial in this review used the most potent statin medication,
atorvastatin, as its treatment group. Additional research with using higher doses and a
more potent statin may prove to be beneficial in men with ED.
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